Evidence map›Paper›PMID 41803739›Full record

ArticleBMC pediatrics2026

Unveiling the unexpected: refractory rickets as an uncommon presentation of tyrosinemia type I.

Meenakshi B Ramanna, Mahesh Kamate, Bhavana Koppad

Abstract readCase Reports
In one paragraph

Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meenakshi B RamannaDepartment of Paediatrics, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India. meenakshi.br@gmail.com.ORCID 0000-0001-9700-681X
Mahesh KamateDepartment of Paediatric Neurology, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India.
Bhavana KoppadDepartment of Paediatrics, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTyrosinemia type I is a rare autosomal recessive inborn error of metabolism caused by deficiency of fumarylacetoacetate hydrolase (FAH), an enzyme essential for the final breakdown of tyrosine. The enzyme defect leads to accumulation of toxic metabolites, primarily affecting the liver, kidneys, and brain. Typically, diagnosed in infancy due to acute or chronic liver dysfunction, refractory rickets is an uncommon presentation. We report a child with tyrosinemia type I presenting with refractory rickets and hepatosplenomegaly but with preserved liver function. CASE PRESENTATION: A three-year-old child presented with bilateral limb deformities unresponsive to multiple courses of vitamin D and calcium. The child also exhibited floppiness, polyuria, and polydipsia. Evaluation revealed hepatomegaly and hypophosphatemic rickets secondary to Fanconi syndrome, later confirmed to be due to tyrosinemia type I. The child was treated with phosphate supplementation, nitisinone, and a tyrosine- and phenylalanine-restricted diet, with favorable follow-up.

conclusionTyrosinemia type I may present beyond infancy with renal-predominant manifestations such as refractory rickets and preserved hepatic function. Early diagnosis and treatment are essential to prevent progression and mortality.

Indexed as

RicketsRickets, HypophosphatemicTyrosinemiasChild, PreschoolCyclohexanonesFanconi SyndromeHepatomegalyHumansMaleNitrobenzoatesCyclohexanonesnitisinoneNitrobenzoatesFanconi syndromeHypophosphatemic ricketsNitisinoneRefractory ricketsTyrosinemia

Identifiers

PMID41803739
PMCPMC13085767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.